Management of Cirrhosis in Diabetes: A Pragmatic Approach to the Patient

Abstract

As the global burden of cirrhosis shifts toward metabolic dysfunction–associated steatotic liver disease (MASLD), diabetes and metabolic syndrome act as key upstream drivers of liver injury. At the same time, diabetes is increasingly recognized even in cirrhosis of non-metabolic etiologies, including viral hepatitis, reflecting both shared risk factors and cirrhosis-related disturbances in glucose homeostasis.

This coexistence amplifies morbidity, mortality, and therapeutic complexity, while conventional diabetes paradigms often prove inadequate in management of cirrhosis. This review synthesizes current evidence and proposes a pragmatic framework for managing diabetes across the full spectrum of cirrhosis. We examine the evolving concept of hepatogenous diabetes, limitations of HbA1c in advanced liver disease, and the complementary roles of oral glucose tolerance testing and continuous glucose monitoring in improving diagnostic accuracy.

The pharmacologic landscape is critically evaluated, integrating contemporary diabetes guidelines with hepatic stage–specific considerations. Metformin remains the backbone of therapy in compensated cirrhosis. Among newer agents, GLP-1 receptor agonists and SGLT2 inhibitors show promise in compensated disease, particularly in patients with MASLD and cardio-renal comorbidities. In contrast, sulfonylureas, insulin secretagogues, and agents associated with fluid retention require caution or avoidance as hepatic reserve declines.

Insulin therapy remains the cornerstone in decompensated cirrhosis and during hospitalization, where conservative dosing and dynamic titration are essential to minimize hypoglycemia. The review emphasizes nutritional optimization, frequent reassessment, and coordinated hepatology–endocrinology care. As diabetes in cirrhosis increasingly reflects the convergence of two metabolic disorders, management must prioritize hepatic safety, metabolic stability, and individualized outcomes over rigid glycemic targets.